Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic PD-L1 Positive (CPS≥1) Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab

NCT05075122 is registered in ClinicalTrials.gov with Martin-Luther-Universität Halle-Wittenberg as lead sponsor.

NCT NCT05075122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05075122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic PD-L1 Positive (CPS≥1) Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab
Lead sponsor
Martin-Luther-Universität Halle-Wittenberg
Phase
Phase 2
Overall status
Unknown status
Start date
August 2, 2021
Completion date
February 28, 2025
Enrollment
75 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma